Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Operating Leases (2019 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Operating Leases for 7 consecutive years, with $404165.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases rose 456.42% year-over-year to $404165.0, compared with a TTM value of $404165.0 through Sep 2025, up 456.42%, and an annual FY2024 reading of $33815.0, down 43.47% over the prior year.
  • Operating Leases was $404165.0 for Q3 2025 at Kiora Pharmaceuticals, down from $430405.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $430405.0 in Q2 2025 and bottomed at $4764.0 in Q3 2022.
  • Average Operating Leases over 5 years is $138118.9, with a median of $82322.0 recorded in 2024.
  • The sharpest move saw Operating Leases plummeted 98.16% in 2022, then soared 456.42% in 2025.
  • Year by year, Operating Leases stood at $90566.0 in 2021, then plummeted by 94.74% to $4764.0 in 2022, then soared by 1155.71% to $59822.0 in 2023, then tumbled by 43.47% to $33815.0 in 2024, then skyrocketed by 1095.22% to $404165.0 in 2025.
  • Business Quant data shows Operating Leases for KPRX at $404165.0 in Q3 2025, $430405.0 in Q2 2025, and $159024.0 in Q1 2025.